Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.55 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376845 | 0.84 | USP2 (0.60) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL376904 | 0.84 | F2 (0.72) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL10222720 | 0.83 | MGLL (0.46) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL10222721 | 0.83 | MGLL (0.43) | CHRNA7CHRNA10CHRNA9F2PRSS1 | |
| SCHEMBL3491543 | 0.82 | MEN1 (0.51) | MEN1ALDH1A1KMT2AUSP2PARP14 | |
| SCHEMBL15159783 | 0.80 | MGLL (0.41) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL3883363 | 0.80 | MAPT (0.61) | CHRNA7CHRNA10CHRNA9F2PRSS1 | |
| SCHEMBL4631061 | 0.79 | PARP10 (0.43) | CHRNA7CHRNA10CHRNA9ITGB3ITGA2B | |
| SCHEMBL30453478 | 0.79 | ITGB3 (0.48) | CHRNA7CHRNA10CHRNA9F2PRSS1 | |
| SCHEMBL1397464 | 0.79 | CHEK1 (0.69) | CHRNA7CHRNA10CHRNA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | CHRNA7 4285/4885CHRNA10 4259/4885CHRNA9 4345/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | CHRNA7 4285/4885CHRNA10 4259/4885CHRNA9 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.